Showing results (111-120 of 330) with videos related to
Sort By:
Pageof 33
Scientific Reports|October 21, 2020
The albumin-bilirubin score as a predictor of outcomes in Japanese patients with PBC: an analysis using time-dependent ROCTakanori Ito, Masatoshi Ishigami, Hikaru Morooka, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 28, 2021
Association of liver stiffness and steatosis with hepatocellular carcinoma development in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological responseToshifumi Tada, Takashi Nishimura, Tomomitsu Matono, et al.British Journal of Cancer|January 13, 2017
Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillancePhilip Johnson, Sarah Berhane, Chiaki Kagebayashi, et al.Journal of Gastroenterology and Hepatology|April 16, 2020
Use of hepatitis B virus core-related antigen to evaluate natural history of chronic hepatitis BHenry Lik Yuen Chan, Satoshi Yasuda, Grace Lai Hung Wong, et al.Cancers|November 11, 2022
Modified Albumin-Bilirubin Grade and Alpha-Fetoprotein Score (mALF Score) for Predicting the Prognosis of Hepatocellular Carcinoma after HepatectomyMasaki Kaibori, Kengo Yoshii, Kosuke Matsui, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 19, 2021
Severity of liver fibrosis using shear wave elastography is influenced by hepatic necroinflammation in chronic hepatitis patients, but not in cirrhotic patientsChikage Nakano, Takashi Nishimura, Toshifumi Tada, et al.Liver Cancer|February 20, 2020
Treatment of Intermediate-Stage Hepatocellular Carcinoma in Japan: Position of Curative TherapiesKazuya Kariyama, Kazuhiro Nouso, Akiko Wakuta, et al.Liver Cancer|December 7, 2023
Attempt to Establish Prognostic Predictive System for Hepatocellular Carcinoma Using Artificial Intelligence for Assistance with Selection of Treatment ModalityAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.Journal of Gastroenterology|October 8, 2010
High ability to predict the treatment outcome of peginterferon and ribavirin combination therapy based on the reduction in HCV RNA levels at 4 weeks after starting therapy and amino acid substitutions in the hepatitis C virus in patients infected with HCV genotype 1bHidenori Toyoda, Takashi Kumada, Seiki Kiriyama, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 24, 2013
Oral supplementation with branched-chain amino acid granules prevents hepatocarcinogenesis in patients with hepatitis C-related cirrhosis: A propensity score analysisToshifumi Tada, Takashi Kumada, Hidenori Toyoda, et al.Pageof 33